Evaluate Efficacy and Safety of "Kamada-AAT for Inhalation" in Patients With AATD (InnovAATe)

  • STATUS
    Recruiting
  • End date
    May 23, 2023
  • participants needed
    220
  • sponsor
    Kamada, Ltd.
Updated on 21 February 2022
COPD
deficiency
pulmonary function test
blood test
chronic obstructive pulmonary disease
lung disease
bronchodilator
forced expiratory volume
inhalations
emphysema
protease inhibitor
washed out
neutrophil elastase
alpha1-proteinase inhibitor (human)

Summary

Alpha-antitrypsin (AAT) is a member of the serpin family of proteinase inhibitors and is to a large extent responsible for restricting proteinases, notably neutrophil elastase, and proteinase 3, which might otherwise attack the lung tissue. Individuals with a genetic deficiency of alpha-1-antitrypsin (AATD) are at a significantly increased risk (80-100%) of developing emphysema. This study is designed to administer a solution of AAT by nebulizer so that patients can inhale the drug instead of requiring infusions as in current treatment. A significant advantage of inhalation is that the AAT is directly transferred to the lungs, which is the site most in need of the protein. Previous results show that in addition to the added convenience, three times higher concentrations of AAT can be achieved in the lungs by inhalation than by intravenous infusions. To date, more than 220 patients have completed Inhalation studies for several indications.

The current study population will consist of adult patients with congenital alpha-1 antitrypsin (AAT) deficiency who have moderate airflow limitation (forced expiratory volume in 1 second 50% [FEV1] 80% of predicted) and FEV1/slow vital capacity [SVC] 70% and who have not experienced two or more moderate or one or more severe exacerbations of COPD during the past year. A total of 220 patients will be recruited, and after 4 weeks practice inhaling saline with the nebulizer, will be randomized 1:1 to inhale either 80 mg/day "Kamada-AAT for Inhalation" or a placebo with identical appearance. Patients will be treated for 104 weeks and then followed up for a further 26 weeks. Over this time there will be 13 visits to the clinical study site for evaluation of lung function by blood tests and CT densitometry. In addition the patients will be required to fill out a daily e-diary with details of the inhalations and will also report their daily symptoms.

Details
Condition Alpha 1-Antitrypsin Deficiency
Treatment placebos, Alpha 1-Antitrypsin
Clinical Study IdentifierNCT04204252
SponsorKamada, Ltd.
Last Modified on21 February 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Diagnosis of severe AAT deficiency, i.e. patients with either Pi(ZZ), Pi(Z/Null), or Pi(Null/Null) genotypes confirmed by genotype blood test documented prior to screening
Serum AAT levels 11 M at screening
Lung disease with clinical evidence of airflow limitation (post bronchodilator FEV1/SVC 70%) at screening
50% FEV1 80% of predicted post-bronchodilator at screening
Patients who are either nave or washed out of any AAT treatment (by IV) for at least 8 weeks prior to randomization
Age between 18 to 65 years inclusive at screening
Able to read and sign informed consent and willing to participate in the study
Males or non-pregnant, non-lactating females whose screening pregnancy test is negative, who are using contraceptive methods deemed reliable by the investigator, who are post-menopausal, or are surgically sterilized
High compliance during run in defined as study medication use and e-Diary compliance for at least 20 out of the 28 days of run in

Exclusion Criteria

Immunoglobulin A (IgA) absolute deficiency defined as serum IgA levels < 0.05 g/L at screening
History of life-threatening transfusion reaction(s), allergy, anaphylactic reaction, or systemic response to human plasma-derived products
Two or more moderate or any severe exacerbation(s) within the year prior to the baseline visit
A moderate exacerbation within 6 weeks prior to the baseline
Use of oral or parenteral glucocorticoids in doses above 10 mg of prednisone daily or equivalent generics (substance and dose)
Clinically significant inter-current illnesses (except for respiratory or liver disease secondary to AAT deficiency), including: cardiac, hepatic, renal, endocrine, neurological, hematological, neoplastic, immunological, skeletal, or other. Patients might be included after consultation with the treating physician and the sponsor if, in the opinion of the Investigator, their condition will not interfere with the safety, compliance or other aspects of this study
Hospitalization for any cause 6 weeks prior to screening
History of lung or liver transplant
On any thoracic or hepatic surgery waiting list
Any lung surgery within the past two years (including bronchoscopic lung volume reduction)
Any smoking within the year prior to screening
Evidence of alcohol abuse or history of alcohol abuse, or use of illegal drugs and/or abuse of legally prescribed drugs in the last 5 years prior to screening
Acute or chronic hepatitis (hepatitis A, hepatitis B, hepatitis C), and/or positive human immunodeficiency virus (HIV) serology
Signs of significant abnormalities in serum hematology, serum chemistry, serum inflammatory / immunogenic markers and urinalysis per investigator judgment, taking into considerations the potential effects of the AAT deficiency
Signs of significant abnormalities in ECG per investigator judgment at screening
Presence of psychiatric/ mental disorder or any other medical disorder that might impair the patient's ability to give informed consent or to comply with the requirements of the study protocol. If, in the opinion of the Investigator, the condition will not interfere with the compliance or other aspects of this study, the patient might be included after consultation with the treating physician and the sponsor
Previous exposure to inhaled AAT
Participation in another clinical trial involving investigational medication or interventional treatment within 30 days and/or last dose 5 half-lives prior to screening visit
Inability to attend scheduled clinic visits and/or comply with study protocol
Any other factor that, in the opinion of the investigator, would prevent the patient from complying with the requirements of the protocol
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note